Neurescence, a biotechnology company specializing in optical imaging technology, is excited to announce that it has received $350,000 funding from Business Development Bank of Canada (BDC) in preparation for the upcoming new product launch and expansion of its sales and marketing team.

Neurescence’s proprietary multiscopes™ enable multi-region and multi-colour functional imaging and stimulation within the brain and spinal cord in freely behaving animals. Neurescence products have the potential to help researchers make an impact in fundamentally understanding the brain function, as well as providing deep insight into various disease mechanisms, in fields such as Parkinson’s, Alzheimer’s, Dementia and Epilepsy.

Neurescence consists of a strong technical and business development team. With the initial product, Quartet®, in the market, Neurescence is planning to strengthen its sales and marketing team to further prepare for its upcoming new product launch, Chromatone™ through the funding received from BDC.

“This fund is extremely valuable as it will assist us in building a stronger sales and marketing team that will facilitate the dissemination of our technologies to neuroscience researchers all over the world. Our technology will help fulfill the need of neuroscientists to understand the brain and discover better assessment and novel therapies for neurological and neuropsychiatric diseases such as Depression, Schizophrenia, Epilepsy and Alzheimer’s.” says Yasaman Soudagar, co-Founder and CEO of Neurescence.

“It has certainly been a pleasure to work with Yasaman and the team at Neurescence to complete their recent funding. As one of the leading companies in the world that utilizes unique technology to further simultaneous multiple region imaging, this team is truly passionate about understanding and paving the way in neuronal long-range circuitries. They are most certainly an impressive and dedicated team of scientists, engineers, and entrepreneurs who are diligently working toward finding the best assessment tools for brain disease and effective therapeutics. We see a bright future ahead.” says Jasmin Ganie-Hobbs, Senior Development Banker of BDC.

About BDC:

The Business Development Bank of Canada (BDC), founded in 1944, is the bank for Canadian entrepreneurs. It provides access to financing, as well as advisory services to help Canadian businesses grow and succeed. Its investment arm, BDC Capital, offers a wide range of risk capital solutions. For more than 75 years, BDC’s only purpose has been to support entrepreneurs in all industries and at all stages of growth.

About Neurescence:

Neurescence was founded in 2015 by a team of scientists and medical professionals with the goal of finding better treatments for diseases of the central nervous system through advancing scientific research. The company combines its novel optical imaging technology with machine learning to overcome critical medicinal and clinical challenges for overcoming neurological and psychiatric conditions.